APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Haemophilia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Haemophilia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173996670320 December 2025198 pages

Choose your research edition.

Industry ResearchHaemophilia Treatment Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Haemophilia Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Haemophilia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Haemophilia Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Haemophilia Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Haemophilia Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Haemophilia Treatment include Takeda, Novo Nordisk, Roche, Pfizer, Bayer, Dimension Therapeutics, CSL Behring, Catalyst BioSciences and Aptevo Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Haemophilia Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Haemophilia Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Haemophilia Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Haemophilia Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Haemophilia Treatment Segment by Company

Takeda

Novo Nordisk

Roche

Pfizer

Bayer

Dimension Therapeutics

CSL Behring

Catalyst BioSciences

Aptevo Therapeutics

Alnylam Pharmaceuticals

Haemophilia Treatment Segment by Type

Haemophilia A

Haemophilia B

Haemophilia Treatment Segment by Application

Hospital

Pharmaceutical Companies

Other

Haemophilia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Haemophilia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Haemophilia Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Haemophilia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Haemophilia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Haemophilia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Haemophilia Treatment Industry Trends Table 2. Haemophilia Treatment Industry Drivers Table 3. Haemophilia Treatment Industry Opportunities and Challenges Table 4. Haemophilia Treatment Industry Restraints Table 5. Global Haemophilia Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Haemophilia Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Haemophilia Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Haemophilia Treatment Sales Market Share by Manufacturers Table 9. Global Haemophilia Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Haemophilia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Haemophilia Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Haemophilia Treatment Manufacturers, Product Type & Application Table 13. Global Haemophilia Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Haemophilia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Haemophilia A Table 17. Major Manufacturers of Haemophilia B Table 18. Global Haemophilia Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Haemophilia Treatment Sales by Type (2021-2026) & (k units) Table 20. Global Haemophilia Treatment Sales by Type (2027-2032) & (k units) Table 21. Global Haemophilia Treatment Sales Market Share by Type (2021-2026) Table 22. Global Haemophilia Treatment Sales Market Share by Type (2027-2032) Table 23. Global Haemophilia Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Haemophilia Treatment Revenue by Type (2021-2026) & (k units) Table 25. Global Haemophilia Treatment Revenue by Type (2027-2032) & (k units) Table 26. Global Haemophilia Treatment Revenue Market Share by Type (2021-2026) Table 27. Global Haemophilia Treatment Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Pharmaceutical Companies Table 30. Major Manufacturers of Other Table 31. Global Haemophilia Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Haemophilia Treatment Sales by Application (2021-2026) & (k units) Table 33. Global Haemophilia Treatment Sales by Application (2027-2032) & (k units) Table 34. Global Haemophilia Treatment Sales Market Share by Application (2021-2026) Table 35. Global Haemophilia Treatment Sales Market Share by Application (2027-2032) Table 36. Global Haemophilia Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Haemophilia Treatment Revenue by Application (2021-2026) & (k units) Table 38. Global Haemophilia Treatment Revenue by Application (2027-2032) & (k units) Table 39. Global Haemophilia Treatment Revenue Market Share by Application (2021-2026) Table 40. Global Haemophilia Treatment Revenue Market Share by Application (2027-2032) Table 41. Global Haemophilia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Haemophilia Treatment Sales by Region (2021-2026) & (k units) Table 43. Global Haemophilia Treatment Sales Market Share by Region (2021-2026) Table 44. Global Haemophilia Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Haemophilia Treatment Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Haemophilia Treatment Sales by Country (2021-2026) & (k units) Table 48. North America Haemophilia Treatment Sales by Country (2027-2032) & (k units) Table 49. Europe Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Haemophilia Treatment Sales by Country (2021-2026) & (k units) Table 51. Europe Haemophilia Treatment Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Haemophilia Treatment Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Haemophilia Treatment Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Haemophilia Treatment Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Haemophilia Treatment Sales by Country (2027-2032) & (k units) Table 58. Global Haemophilia Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Haemophilia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Haemophilia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Haemophilia Treatment Revenue Market Share by Region (2021-2026) Table 62. Global Haemophilia Treatment Revenue Market Share by Region (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Takeda Haemophilia Treatment Product Portfolio Table 67. Takeda Recent Development Table 68. Novo Nordisk Company Information Table 69. Novo Nordisk Business Overview Table 70. Novo Nordisk Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novo Nordisk Haemophilia Treatment Product Portfolio Table 72. Novo Nordisk Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche Haemophilia Treatment Product Portfolio Table 77. Roche Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Haemophilia Treatment Product Portfolio Table 82. Pfizer Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bayer Haemophilia Treatment Product Portfolio Table 87. Bayer Recent Development Table 88. Dimension Therapeutics Company Information Table 89. Dimension Therapeutics Business Overview Table 90. Dimension Therapeutics Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Dimension Therapeutics Haemophilia Treatment Product Portfolio Table 92. Dimension Therapeutics Recent Development Table 93. CSL Behring Company Information Table 94. CSL Behring Business Overview Table 95. CSL Behring Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. CSL Behring Haemophilia Treatment Product Portfolio Table 97. CSL Behring Recent Development Table 98. Catalyst BioSciences Company Information Table 99. Catalyst BioSciences Business Overview Table 100. Catalyst BioSciences Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Catalyst BioSciences Haemophilia Treatment Product Portfolio Table 102. Catalyst BioSciences Recent Development Table 103. Aptevo Therapeutics Company Information Table 104. Aptevo Therapeutics Business Overview Table 105. Aptevo Therapeutics Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Aptevo Therapeutics Haemophilia Treatment Product Portfolio Table 107. Aptevo Therapeutics Recent Development Table 108. Alnylam Pharmaceuticals Company Information Table 109. Alnylam Pharmaceuticals Business Overview Table 110. Alnylam Pharmaceuticals Haemophilia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Alnylam Pharmaceuticals Haemophilia Treatment Product Portfolio Table 112. Alnylam Pharmaceuticals Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Haemophilia Treatment Distributors List Table 116. Haemophilia Treatment Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Haemophilia Treatment Product Image Figure 2. Global Haemophilia Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Haemophilia Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Haemophilia Treatment Sales (2021-2032) & (k units) Figure 5. Global Haemophilia Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Haemophilia Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Haemophilia A Image Figure 9. Haemophilia B Image Figure 10. Global Haemophilia Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Haemophilia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Haemophilia Treatment Sales Market Share by Type (2021-2032) Figure 13. Global Haemophilia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Haemophilia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Haemophilia Treatment Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Pharmaceutical Companies Image Figure 18. Other Image Figure 19. Global Haemophilia Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Haemophilia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Haemophilia Treatment Sales Market Share by Application (2021-2032) Figure 22. Global Haemophilia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Haemophilia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Haemophilia Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Haemophilia Treatment Sales Market Share by Country (2021-2032) Figure 27. U.S. Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Haemophilia Treatment Sales Market Share by Country (2021-2032) Figure 32. Germany Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Haemophilia Treatment Sales Market Share by Country (2021-2032) Figure 39. China Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Haemophilia Treatment Sales Market Share by Country (2021-2032) Figure 47. Brazil Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Haemophilia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Haemophilia Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Haemophilia Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Haemophilia Treatment Revenue (2021-2032) & (US$ Million) Figure 58. North America Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Haemophilia Treatment Revenue (2021-2032) & (US$ Million) Figure 60. Europe Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Haemophilia Treatment Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Haemophilia Treatment Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Haemophilia Treatment Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Haemophilia Treatment Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Haemophilia A
  • Haemophilia B
Applications
  • Hospital
  • Pharmaceutical Companies
  • Other
Companies covered
  • Takeda
  • Novo Nordisk
  • Roche
  • Pfizer
  • Bayer
  • Dimension Therapeutics
  • CSL Behring
  • Catalyst BioSciences
  • Aptevo Therapeutics
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Haemophilia Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Haemophilia Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Haemophilia Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Haemophilia Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Haemophilia Treatment Market Dynamics
  1. 2.1 Haemophilia Treatment Industry Trends
  2. 2.2 Haemophilia Treatment Industry Drivers
  3. 2.3 Haemophilia Treatment Industry Opportunities and Challenges
  4. 2.4 Haemophilia Treatment Industry Restraints
3 Haemophilia Treatment Market by Manufacturers
  1. 3.1 Global Haemophilia Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Haemophilia Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Haemophilia Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Haemophilia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Haemophilia Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Haemophilia Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Haemophilia Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Haemophilia Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Haemophilia Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Haemophilia Treatment Tier 1, Tier 2, and Tier 3
4 Haemophilia Treatment Market by Type
  1. 4.1 Haemophilia Treatment Type Introduction
  2. 4.1.1 Haemophilia A
  3. 4.1.2 Haemophilia B
  4. 4.2 Global Haemophilia Treatment Sales by Type
  5. 4.2.1 Global Haemophilia Treatment Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Haemophilia Treatment Sales by Type (2021-2032)
  7. 4.2.3 Global Haemophilia Treatment Sales Market Share by Type (2021-2032)
  8. 4.3 Global Haemophilia Treatment Revenue by Type
  9. 4.3.1 Global Haemophilia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Haemophilia Treatment Revenue by Type (2021-2032)
  11. 4.3.3 Global Haemophilia Treatment Revenue Market Share by Type (2021-2032)
5 Haemophilia Treatment Market by Application
  1. 5.1 Haemophilia Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmaceutical Companies
  4. 5.1.3 Other
  5. 5.2 Global Haemophilia Treatment Sales by Application
  6. 5.2.1 Global Haemophilia Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Haemophilia Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Haemophilia Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Haemophilia Treatment Revenue by Application
  10. 5.3.1 Global Haemophilia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Haemophilia Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Haemophilia Treatment Revenue Market Share by Application (2021-2032)
6 Global Haemophilia Treatment Sales by Region
  1. 6.1 Global Haemophilia Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Haemophilia Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Haemophilia Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Haemophilia Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Haemophilia Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Haemophilia Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Haemophilia Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Haemophilia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Haemophilia Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Haemophilia Treatment Revenue by Region
  1. 7.1 Global Haemophilia Treatment Revenue by Region
  2. 7.1.1 Global Haemophilia Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Haemophilia Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Haemophilia Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Haemophilia Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Haemophilia Treatment Revenue (2021-2032)
  8. 7.2.2 North America Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Haemophilia Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Haemophilia Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Haemophilia Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Haemophilia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Haemophilia Treatment Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Haemophilia Treatment Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Haemophilia Treatment Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Haemophilia Treatment Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Haemophilia Treatment Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Dimension Therapeutics
  32. 8.6.1 Dimension Therapeutics Company Information
  33. 8.6.2 Dimension Therapeutics Business Overview
  34. 8.6.3 Dimension Therapeutics Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dimension Therapeutics Haemophilia Treatment Product Portfolio
  36. 8.6.5 Dimension Therapeutics Recent Developments
  37. 8.7 CSL Behring
  38. 8.7.1 CSL Behring Company Information
  39. 8.7.2 CSL Behring Business Overview
  40. 8.7.3 CSL Behring Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CSL Behring Haemophilia Treatment Product Portfolio
  42. 8.7.5 CSL Behring Recent Developments
  43. 8.8 Catalyst BioSciences
  44. 8.8.1 Catalyst BioSciences Company Information
  45. 8.8.2 Catalyst BioSciences Business Overview
  46. 8.8.3 Catalyst BioSciences Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Catalyst BioSciences Haemophilia Treatment Product Portfolio
  48. 8.8.5 Catalyst BioSciences Recent Developments
  49. 8.9 Aptevo Therapeutics
  50. 8.9.1 Aptevo Therapeutics Company Information
  51. 8.9.2 Aptevo Therapeutics Business Overview
  52. 8.9.3 Aptevo Therapeutics Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Aptevo Therapeutics Haemophilia Treatment Product Portfolio
  54. 8.9.5 Aptevo Therapeutics Recent Developments
  55. 8.10 Alnylam Pharmaceuticals
  56. 8.10.1 Alnylam Pharmaceuticals Company Information
  57. 8.10.2 Alnylam Pharmaceuticals Business Overview
  58. 8.10.3 Alnylam Pharmaceuticals Haemophilia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alnylam Pharmaceuticals Haemophilia Treatment Product Portfolio
  60. 8.10.5 Alnylam Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Haemophilia Treatment Value Chain Analysis
  2. 9.1.1 Haemophilia Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Haemophilia Treatment Production Mode & Process
  6. 9.2 Haemophilia Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Haemophilia Treatment Distributors
  9. 9.2.3 Haemophilia Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst